Emcure launches ₹2,200-a-week weight-loss drug in Novo Nordisk partnership
Despite an impending patent cliff in 2026 that will invite generic competition from companies like Sun Pharma and Dr. Reddy's, Emcure’s leadership believes the ‘innovator edge’ and a robust metabolic portfolio will secure long-term market dominance.
Despite an impending patent cliff in 2026 that will invite generic competition from companies like Sun Pharma and Dr. Reddy's, Emcure’s leadership believes the ‘innovator edge’ and a robust metabolic portfolio will secure long-term market dominance.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
